Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
about
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/macrophagic differentiation status of promyelocytic leukemia cells.Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
P2860
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@en
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@nl
type
label
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@en
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@nl
prefLabel
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@en
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@nl
P2093
P2860
P356
P1433
P1476
Treatment by design in leukemi ...... , Pennsylvania, December 2002.
@en
P2093
Bertrand FE
Schiffer CA
Steelman LS
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403156
P577
2003-12-01T00:00:00Z
P5875
P6179
1006940432